Difference between revisions of "Escitalopram-dosulepine"

From Psychiatrienet
Jump to: navigation, search
Line 4: Line 4:
 
| stop = {{StopEscitalopram}}
 
| stop = {{StopEscitalopram}}
 
| start =  
 
| start =  
* '''Day 8:''' start administration of dosulepine in a normal dosage of 50-75 mg/day.
+
* '''Day 9:''' start administration of dosulepine in a normal dosage of 50-75 mg/day.
* '''Day 15:''' increase dosage of dosulepine if necessary.  
+
* '''Day 16:''' increase dosage of dosulepine if necessary.  
 
| info =  
 
| info =  
 
* “Start low, go slow” for dosulepine is not required, but caution is necessary.
 
* “Start low, go slow” for dosulepine is not required, but caution is necessary.
 
* {{theorSS}}
 
* {{theorSS}}
 
}}
 
}}

Revision as of 13:28, 28 October 2015

Escitalopram
Type Antidepressant
Group SSRI
links
Medscape Escitalopram
PubChem 10832572
PubMed Escitalopram
Kompas (Dutch) Escitalopram
Wikipedia Escitalopram
dosulepin
Type antidepressant
Group TCA
links
ATC-code N06AA16
PubChem 13473
PubMed dosulepin
Kompas (Dutch) dosulepin
Wikipedia dosulepin

Switch medication from escitalopram to dosulepine.[1] [2]

Nietinrijdenbord.png Stop escitalopram
  • Before day 1: gradually reduce dosage of escitalopram to a maximum of 10 mg/day, when this dosage is >10 mg/day.
  • Day 1: reduce dosage of escitalopram to a maximum of 5 mg/day.
  • Day 8: stop administration of escitalopram.
Eenrichtingbord.png Start dosulepine
  • Day 9: start administration of dosulepine in a normal dosage of 50-75 mg/day.
  • Day 16: increase dosage of dosulepine if necessary.
Infobord.png More information
  • “Start low, go slow” for dosulepine is not required, but caution is necessary.
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.